TY - JOUR
T1 - Navigating the open innovation paradox
T2 - an integrative framework for adopting open innovation in pharmaceutical R&D in developing countries
AU - Bhatnagar, Bhawani
AU - Dörfler, Viktor
AU - MacBryde, Jillian
PY - 2023/12/20
Y1 - 2023/12/20
N2 - In this paper, we combine evidence from eight Indian pharmaceutical firms with extant literature and global best practices to conceptualize an integrative framework addressing the open innovation paradox (OIP), i.e., the tension between intellectual protection and openness. Firms in developing countries face additional challenges in the adoption of open innovation, such as the prevalence of open science norms, weak technology transfer systems, and mistrust between universities and industry; therefore, they employ open innovation selectively for pharmaceutical research. Prior research has examined the strategies to resolve OIP in the context of developed countries; the integrative framework proposed in this paper describes strategies for resolving the OIP in the context of developing countries. This framework illuminates the coping processes of the case firms and provides guidelines to uplift and accelerate the adoption of open innovation strategies in developing countries' pharmaceutical sectors, and thus provides value to both theory and praxis.
AB - In this paper, we combine evidence from eight Indian pharmaceutical firms with extant literature and global best practices to conceptualize an integrative framework addressing the open innovation paradox (OIP), i.e., the tension between intellectual protection and openness. Firms in developing countries face additional challenges in the adoption of open innovation, such as the prevalence of open science norms, weak technology transfer systems, and mistrust between universities and industry; therefore, they employ open innovation selectively for pharmaceutical research. Prior research has examined the strategies to resolve OIP in the context of developed countries; the integrative framework proposed in this paper describes strategies for resolving the OIP in the context of developing countries. This framework illuminates the coping processes of the case firms and provides guidelines to uplift and accelerate the adoption of open innovation strategies in developing countries' pharmaceutical sectors, and thus provides value to both theory and praxis.
KW - open innovation paradox
KW - patenting
KW - licensing
KW - collaboration
U2 - 10.1007/s10961-022-09958-6
DO - 10.1007/s10961-022-09958-6
M3 - Article
SN - 0892-9912
VL - 48
SP - 2204
EP - 2248
JO - Journal of Technology Transfer
JF - Journal of Technology Transfer
IS - 6
ER -